Granules India Ltd (GRANULES):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Granules India Ltd (GRANULES) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10153
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Granules India Ltd (Granules) is a pharmaceutical manufacturing company, which carries out the research, development and manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). The company manufactures Paracetomol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol. It has premier facilities for the manufacture of APIs, PFIs and FDs. With offices in India, the US, the UK, China and Colombia, the company offers products and solutions to companies across the world. Granules also provides contract research and manufacturing services. Its key clients include leading generic and branded pharmaceutical companies. Granules is headquartered in Hyderabad, Telangana, India.

Granules India Ltd (GRANULES) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Granules India Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Granules India Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Granules Pharma Enters into Licensing Agreement with USpharma Windlas 11
Equity Offering 12
Granules India Raises USD77.3 Million in Qualified Institutions Placement of Equity Shares 12
Acquisition 13
Granules Pharma to Acquire 12.5% Stake in Uspharma 13
Granules India Acquires Auctus Pharma for USD19 Million 14
Granules India Ltd – Key Competitors 15
Granules India Ltd – Key Employees 16
Granules India Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Financial Announcements 18
May 24, 2018: Granules India’s Total Income increases by 18% to INR 1,703 Cr 18
Feb 08, 2018: Granules India’s Revenue from operation increases by 14% to INR 411 Cr 19
Nov 09, 2017: Granules India’s Revenue from operation increases by 8% to INR 393 Cr 20
Aug 14, 2017: Granules India Reported Its First Quarter Financial Results 2017 21
May 11, 2017: Granules India’s Revenue increases 4% to Rs. 1,435 Cr.; Net Profit surges 34% to Rs. 165 Cr 22
Jan 28, 2017: Granules India’s Net Profit rises by 34% to Rs. 39 Cr 23
Legal and Regulatory 24
Mar 26, 2018: Granules India’s Gagillapur and Jeedimetla facilities complete US FDA inspection 24
Feb 28, 2018: Granules India’s Chantilly facility received EIR from USFDA 25
Oct 06, 2017: Receipt of establishment report by Granules OmniChem facility from US FDA 26
Feb 03, 2017: Granules India’s Gagillapur facility completed INFARMED reinspection 27
Jan 06, 2017: Granules India’s Gagillapur Facility Completed INFARMED Inspection 28
Other Significant Developments 29
Aug 16, 2017: Granules India Reports Establishment Inspection Report (EIR) From US FDA-Reg. 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Granules India Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Granules India Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Granules Pharma Enters into Licensing Agreement with USpharma Windlas 11
Granules India Raises USD77.3 Million in Qualified Institutions Placement of Equity Shares 12
Granules Pharma to Acquire 12.5% Stake in Uspharma 13
Granules India Acquires Auctus Pharma for USD19 Million 14
Granules India Ltd, Key Competitors 15
Granules India Ltd, Key Employees 16
Granules India Ltd, Subsidiaries 17
Granules India Ltd, Joint Venture 17

List of Figures
Granules India Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Granules India Ltd (GRANULES):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shanghai Institute of Materia Medica Chinese Academy of Sciences-製薬・医療分野:企業M&A・提携分析
    Summary Shanghai Institute of Materia Medica Chinese Academy of Sciences (SIMM) is an educational research institute that offers research and development of traditional Chinese medicine. The institute provides solutions in the areas of drug discovery and drug development. It also provides studies of …
  • Informa PLC (INF):企業の財務・戦略的SWOT分析
    Informa PLC (INF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Birner Dental Management Services Inc (BDMS):企業の財務・戦略的SWOT分析
    Summary Birner Dental Management Services Inc (Perfect Teeth) is a dental care service provider. The company offers dental care services such as orthodontics, pediatric dentistry, periodontics, perio protect, endodontics and oral surgery. It also offers fillings and aesthetic procedures, porcelain v …
  • CBS Corporation (CBS):企業の財務・戦略的SWOT分析
    CBS Corporation (CBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Dynegy Inc (DYN)-エネルギー分野:企業M&A・提携分析
    Summary Dynegy Inc. (Dynegy) is a holding company, which carries out its business through its subsidiaries. The company produces and sells electric energy, capacity and ancillary services primarily on a wholesale basis through its power generation facilities. Dynegy offers its services to integrated …
  • Hana Financial Group Inc.:企業の戦略・SWOT・財務分析
    Hana Financial Group Inc. - Strategy, SWOT and Corporate Finance Report Summary Hana Financial Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Select Medical Holdings Corp (SEM):企業の財務・戦略的SWOT分析
    Summary Select Medical Holdings Corp (Select Medical) is a healthcare service provider that offers outpatient rehabilitation services. The center provides long-term acute care services such as complex infectious disease treatment, respiratory failure, medically complex treatment, neurology, pulmonar …
  • Mesoblast Ltd (MSB):製薬・医療:M&Aディール及び事業提携情報
    Summary Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft ve …
  • Verisante Technology Inc (VRS)-医療機器分野:企業M&A・提携分析
    Summary Verisante Technology Inc (Verisante), develops and commercializes products for the early detection of all forms of skin cancer. The company’s key product offerings include Verisante Aura, Verisante Core and Verisante MSI Camera. The Verisante Aura is used for skin cancer detection, and Veris …
  • Falck Renewables S.p.A. (FKR):企業の財務・戦略的SWOT分析
    Falck Renewables S.p.A. (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Lafarge Malaysia Berhad (LAFMSIA):企業の財務・戦略的SWOT分析
    Summary Lafarge Malaysia Berhad (LMB), formerly Lafarge Malayan Cement Berhad is a construction company that manufactures and markets aggregates, ready-mixed concrete, cement, and related construction and building materials. The company offers cement products such as walcrete, rumah, phoenix, oil we …
  • Triumph Group Inc:戦略・SWOT・企業財務分析
    Triumph Group Inc - Strategy, SWOT and Corporate Finance Report Summary Triumph Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Viralytics Ltd (VLA)-製薬・医療分野:企業M&A・提携分析
    Summary Viralytics Ltd (Viralytics), formerly Psiron Ltd is a provider of development and commercialisation of oncolytic immunotherapies. The company develops oncolytic immunotherapies for the treatment of different types of cancers. It offers cavataktm, a proprietary formulation for the common cold …
  • Gulfport Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Gulfport Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Gulfport Energy Corp (Gulfport) is an oil and gas company that explores, develops and produces oil and natural gas. The company operates its oil and gas exploration and development assets in Uti …
  • Senex Energy Ltd (SXY):石油・ガス:M&Aディール及び事業提携情報
    Summary Senex Energy Ltd (Senex), formerly Victoria Petroleum NL, is an independent upstream oil and gas exploration and production company that acquires, explores and develops oil and gas assets in the Surat Basin and the Cooper Basin. The company extracts natural gas from coal seams. Its oil and g …
  • Valneva SE:企業のM&A・事業提携・投資動向
    Valneva SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Valneva SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Shinhan Financial Group Co Ltd:戦略・SWOT・企業財務分析
    Shinhan Financial Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shinhan Financial Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Itausa – Investimentos Itau SA (ITSA4):企業の財務・戦略的SWOT分析
    Itausa - Investimentos Itau SA (ITSA4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Industrial Alliance Insurance and Financial Services Inc.:企業のM&A・事業提携・投資動向
    Industrial Alliance Insurance and Financial Services Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Industrial Alliance Insurance and Financial Services Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includ …
  • Laboratorios SALVAT SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratorios SALVAT SA (SALVAT) is a pharmaceutical company with focus on the development and commercialization of innovative medicines. The company manufactures drugs in various segments such as personal healthcare, digestive / metabolism, urological conditions, ophthalmological diseases, E …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆